+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Armagen - logo

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions - Product Thumbnail Image

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • Report
  • September 2024
  • 375 Pages
  • Global
From
Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030 - Product Thumbnail Image

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030

  • Report
  • September 2021
  • 150 Pages
  • Global
From
Lysosomal Storage Diseases Market by Disease Type, Type of Therapy, End User - Global Forecast 2025-2030 - Product Thumbnail Image

Lysosomal Storage Diseases Market by Disease Type, Type of Therapy, End User - Global Forecast 2025-2030

  • Report
  • October 2024
  • 181 Pages
  • Global
From
Duchenne Muscular Dystrophy Global Market Report 2024 - Product Thumbnail Image

Duchenne Muscular Dystrophy Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Central Nervous System Collaboration and Licensing Deals 2019-2024 - Product Thumbnail Image

Central Nervous System Collaboration and Licensing Deals 2019-2024

  • Report
  • October 2024
  • 500 Pages
  • Global
From
Hunter Syndrome Treatment - Global Strategic Business Report - Product Thumbnail Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • November 2024
  • 94 Pages
  • Global
From
Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 40 Pages
  • Global
From
Mucopolysaccharidosis I - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Mucopolysaccharidosis I - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
  • Global
From
Hunter Syndrome Treatment Market by Treatment, End User - Global Forecast 2025-2030 - Product Thumbnail Image

Hunter Syndrome Treatment Market by Treatment, End User - Global Forecast 2025-2030

  • Report
  • October 2024
  • 190 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 672 Pages
  • Global
From
Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 1079 Pages
  • Global
From
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 110 Pages
  • Global
From
Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028) - Product Thumbnail Image

Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • Report
  • April 2023
  • 110 Pages
  • Global
From
Hunter Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Metachromatic Leukodystrophy (MLD) - Pipeline Insight, 2024 - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Metachromatic Leukodystrophy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Metachromatic Leukodystrophy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2024
  • 77 Pages
  • Global
From
Rett Syndrome Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Rett Syndrome Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • September 2024
  • 89 Pages
  • Global
From
Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 94 Pages
  • Global
From
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 73 Pages
  • Global
From
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 77 Pages
  • Global
From
Loading Indicator